GoAI
Get started
Zhaoke Ophthalmology Limited logo

Zhaoke Ophthalmology Limited

6622.HK

HKSEHealthcareBiotechnology

Open in GoAI

Latest quote

HK$2.50

−HK$0.03 · -1.19%

Aug 24, 10:55 AM HKTData delayed

6622.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

Zhaoke Ophthalmology Limited is an ophthalmic pharmaceutical company dedicated to researching, developing, and commercializing therapeutic solutions addressing significant unmet medical requirements in the People's Republic of China. The company is advancing a range of medications designed for various ocular conditions, impacting both the anterior and posterior segments of the eye, such as dry eye disease, wet age-related macular degeneration, diabetic macular edema, myopia, and glaucoma. It was previously known as China Ophthalmology Focus Limited. Zhaoke Ophthalmology Limited was established in 2017 and operates from its headquarters in Guangzhou, People's Republic of China.

Industry
Biotechnology
Sector
Healthcare
Headquarters
CN
CEO
Xiaoyi Li
Listed since
Apr 29, 2021
Employees
276

Market position

Day range

Current HK$2.50

52-week range

Current HK$2.50

Open
HK$2.52
Previous close
HK$2.53
Volume
42.5K
0.1× average
Average volume
440.26K
Average daily volume
Market cap
1.37B HKD
Beta
1.08
Market reference 1
50-day average
HK$2.58
-3.10% below average
200-day average
HK$2.9924
-16.46% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-5.64×
P/B (TTM)
0.74×
P/S (TTM)
37.09×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
-32.98%
Operating margin
-856.59%
Net margin
-654.30%

Financial health

Debt / equity
0.19×
Altman Z-score
-1.3
Piotroski F-score
1 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends289%-563%-1415%-2266%Gross margin, FY2023: 75.98%Gross margin, FY2024: 74.72%Gross margin, FY2025: -104.56%Operating margin, FY2023: -2008.36%Operating margin, FY2024: -328.88%Operating margin, FY2025: -855.36%Net margin, FY2023: -2053.54%Net margin, FY2024: -342.58%Net margin, FY2025: -653.60%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2023 75.98%. Gross margin FY2024 74.72%. Gross margin FY2025 -104.56%. Operating margin FY2023 -2008.36%. Operating margin FY2024 -328.88%. Operating margin FY2025 -855.36%. Net margin FY2023 -2053.54%. Net margin FY2024 -342.58%. Net margin FY2025 -653.60%.

Income trends

Revenue

31.15M CNY-55.07%

Operating income

−266.41M CNY-16.85%

Net income

−203.57M CNY+14.28%
Income trends across reported periods289.68M CNY−591.74M CNY−1.47B CNY−2.35B CNYRevenue, FY2023: 18.75M CNYRevenue, FY2024: 69.32M CNYRevenue, FY2025: 31.15M CNYOperating income, FY2021: −364.33M CNYOperating income, FY2022: −404.18M CNYOperating income, FY2023: −376.57M CNYOperating income, FY2024: −227.99M CNYOperating income, FY2025: −266.41M CNYNet income, FY2021: −2.13B CNYNet income, FY2022: −407.32M CNYNet income, FY2023: −385.04M CNYNet income, FY2024: −237.49M CNYNet income, FY2025: −203.57M CNYFY2021FY2022FY2023FY2024FY2025
Revenue FY2023 18.75M CNY. Revenue FY2024 69.32M CNY. Revenue FY2025 31.15M CNY. Operating income FY2021 −364.33M CNY. Operating income FY2022 −404.18M CNY. Operating income FY2023 −376.57M CNY. Operating income FY2024 −227.99M CNY. Operating income FY2025 −266.41M CNY. Net income FY2021 −2.13B CNY. Net income FY2022 −407.32M CNY. Net income FY2023 −385.04M CNY. Net income FY2024 −237.49M CNY. Net income FY2025 −203.57M CNY.
Metric (CNY)FY2025FY2024FY2023FY2022FY2021
Revenue31.15M CNY69.32M CNY18.75M CNY——
Cost of goods sold63.71M CNY17.53M CNY4.5M CNY——
Gross profit−32.57M CNY51.8M CNY14.25M CNY——
Research and development132.46M CNY203.7M CNY333.05M CNY296.43M CNY220.06M CNY
Selling, general, and administrative36.86M CNY134.28M CNY43.16M CNY48.09M CNY65.45M CNY
Operating expenses233.85M CNY279.79M CNY390.81M CNY405.01M CNY364.33M CNY
Interest income43.22M CNY75.23M CNY77.4M CNY30.42M CNY5.04M CNY
Interest expense8.85M CNY9.5M CNY7.92M CNY3.14M CNY1.95M CNY
Depreciation and amortization50.97M CNY33.68M CNY48.7M CNY27.78M CNY21.34M CNY
Operating income−266.41M CNY−227.99M CNY−376.57M CNY−404.18M CNY−364.33M CNY
Net income−203.57M CNY−237.49M CNY−385.04M CNY−407.32M CNY−2.13B CNY

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS
-0.37
FY2025
Latest fiscal-year revenue
31.15M CNY
FY2025 · -55.07% year over year

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend0.11-1.81-3.74-5.66FY21FY22FY23FY24FY25

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend76.26M48.53M20.8M-6.93MFY21FY22FY23FY24FY25

6622.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$195.4

-5.05%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.50

-3.53%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$220.2

-3.42%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.30

-5.29%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.06

-6.11%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$98.90

-3.42%

Continue in GoAI

Research 6622.HK

research.disclaimer